single-dr.php

JDR Vol.4 No.5 pp. 346-351
(2009)
doi: 10.20965/jdr.2009.p0346

Review:

Imported Rabies Cases and Preparedness for Rabies in Japan

Kinjiro Morimoto* and Masayuki Saijo**

*Faculty of Pharmacy, Yasuda Women’s University, 6-13-1 Yasuhigashi, Asaminami-ku, Hiroshima 731-0153, Japan

**Department of Virology 1, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

Received:
May 15, 2009
Accepted:
June 8, 2009
Published:
October 1, 2009
Keywords:
rabies, zoonosis, post-exposure prophylaxis (PEP)
Abstract

Rabies has been causing some 55,000 annual deaths worldwide, mostly in the developing countries in Asia and Africa. At present, safe and effective post-exposure prophylaxis (PEP) has been established and applied to more than 10 million persons each year. Nevertheless, fatal infection of human rabies imported or from wild animals has not been eradicated even in developed countries. In Japan, two imported cases occurred in 2006, the first such cases in 36 years. It is necessary to inform the public about rabies, in particular for overseas tourists, to establish the prompt and appropriate PEP systems, and to improve vaccine supply systems in order to prevent the recurrence of rabies cases in Japan.

Cite this article as:
Kinjiro Morimoto and Masayuki Saijo, “Imported Rabies Cases and Preparedness for Rabies in Japan,” J. Disaster Res., Vol.4, No.5, pp. 346-351, 2009.
Data files:
References
  1. [1] Ministry of Health, Labour and Welfare (MHLW),
    http://www-bm.mhlw.go.jp/houdou/2006/11/h1116-2.html (in Japanese).
  2. [2] MHLW, http://www-bm.mhlw.go.jp/houdou/2006/11/h1122-1.html (in Japanese).
  3. [3] World Health Organization (WHO), “Current WHO guide for rabies pre- and post-exposure treatment in human 2002,”
    (http://www.who.int/rabies/en/WHO_guide_rabies_pre_post_exp_treat_humans.pdf).
  4. [4] N. Takayama, “Rabies Control in Japan,” Jpn. J. Infect. Dis. Vol.53, pp. 93-97, 2000.
  5. [5] WHO, Fact Sheet No.99, 2006,
    http://www.who.int/mediacentre/factsheets/fs099/en/.
  6. [6] Asian Rabies Expert Bureau, “Preventing the incurable: Asian rabies experts advocate rabies control,” Vaccine Vol.24, pp. 3045-3049, 2006.
  7. [7] H. B. Bourhy, L. Dacheux, C. Strady, and A. Mailles, “Rabies in Europe in 2005,” Eurosurveillance Vol.10, pp. 213-216, 2005.
  8. [8] Rabies-Bulletin-Europe, Rabies Information System of the WHO Collaboration Centre for Rabies Surveillance and Research,
    http://www.who-rabies-bulletin.org/.
  9. [9] J. D. Blanton, J. W. Krebs, C. A. Hanlon, and C. E. Rupprecht, “Rabies surveillance in the United States during 2006,” J. Am. Vet. Med. Assoc. Vol.229, pp. 540-556, 2007.
  10. [10] S. L. Messenger, J. S. Smith, and C. E. Rupprecht, “Emerging epidemiology of bat-associated cryptic cases of rabies in human in the United States,” Clinic. Inf. Dis. Vol.35, pp. 738-747, 2002.
  11. [11] Centers for Disease Control and Prevention (CDC), “Investigation of rabies infections in organ donor and transplant recipients - Alabama, Arkansas, Oklahoma, and Texas, 2004,” MMWR Morb. Mortal Wkly Rep. Vol.53, pp. 586-589, 2004.
  12. [12] W. Hellenbrand, et al., “2 Cases of rabies in Germany following organ transplantation,” Eurosurveillance, Vol.10, No.2, 2005.
  13. [13] Ministry of Agriculture, “Forestry and Fisheries (MAFF),”
    http://www.maff.go.jp/aqs/animal/dog/import-index.html
    (in Japanese).
  14. [14] MHLW, “New notification system for the importation of animals,”
    http://www.mhlw.go.jp/english/topics/importanimal/index.html.
  15. [15] CDC, “Temporary unavailability of rabies pre-exposure vaccination,”
    http://www.cdc.gov/rabies/news/2008-05-20_PreEVax.html.
  16. [16] CDC, “Rabies vaccine supply situation,”
    http://www.cdc.gov/rabies/news/RabVaxupdate.html.
  17. [17] WHO, “Rabies vaccines WHO position paper,” Weekly epidemiological Record Vol.82, pp. 425-436, 2007.
  18. [18] P. Gautret et al., “Rabies postexposure prophylaxis in returned injured travelers from France, Australia, and New Zealand: a retrospective study,” J. Travel Med. Vol.15, pp. 25-30, 2008.
  19. [19] WHO, “Initiative for vaccine research Rabies,”
    http://www.who.int/vaccine_research/diseases/zoonotic/en/index5.html.
  20. [20] “Crucell Enters Agreement with Sanofi Pasteur for Next-generation Biological against Rabies,”
    http://investors.crucell.com/C/132631/PR/200801/1179185_5_5.html.
  21. [21] D. Slate et al., “Status of oral rabies vaccination in wild carnivores in the United States,” Virus Res. Vol.111, pp. 68-76, 2005.
  22. [22] D. Nathwani et al., “Fatal Human rabies caused by European bat lyssavirus type 2a infection in Scotland,” Clinic Inf. Dis. Vol.37, pp. 598-601, 2003.
  23. [23] P. P. van Thiel et al., “Fatal case of human rabies (Duvenhage virus) from a bat in Kenya: the Netherlands, December 2007,” Eurosurveillance, Vol.13, No.2, 2008.
  24. [24] R. E. Willoughby et al., “Survival after treatment of rabies with induction of coma,” N. Engl. J. Med. Vol.352, pp. 2508-2514, 2005.

*This site is desgined based on HTML5 and CSS3 for modern browsers, e.g. Chrome, Firefox, Safari, Edge, Opera.

Last updated on Mar. 05, 2021